Palo Alto, CA, United States of America

Flordeliza Melchor-Khan



 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2017-2018

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Flordeliza Melchor-Khan: Innovator in Cancer Treatment

Introduction

Flordeliza Melchor-Khan is a prominent inventor based in Palo Alto, CA (US). She has made significant contributions to the field of cancer treatment, holding 2 patents that focus on innovative methods for addressing various types of cancers. Her work is particularly relevant for patients who are at high risk or have shown resistance to traditional chemotherapy treatments.

Latest Patents

Flordeliza's latest patents include groundbreaking methods for treating cancers. These methods involve administering a therapeutically effective amount of a specific compound to patients in need. The treatments are designed for individuals who may be very high risk for cancer or those who have become refractory to at least one chemotherapy treatment. The cancers targeted by her inventions include hematologic malignancies such as leukemia and lymphoma.

Career Highlights

Flordeliza Melchor-Khan is currently employed at Gilead Sciences, Inc., where she continues to advance her research in cancer therapies. Her work has garnered attention for its potential to improve outcomes for patients facing challenging cancer diagnoses.

Collaborations

Some of her notable coworkers include Julie A Di Paolo and Michael J Hawkins, who contribute to the collaborative environment that fosters innovation at Gilead Sciences, Inc.

Conclusion

Flordeliza Melchor-Khan's contributions to cancer treatment through her patents and work at Gilead Sciences, Inc. highlight her dedication to improving patient care. Her innovative approaches are paving the way for new therapies that could significantly impact the lives of those battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…